Novel Proline Derivatives for Treating COVID-19

COVID-19 is a contagious disease. Paxlovid, a combination of Nirmatrelvir and Ritonavir, was granted emergency use authorization by the United States Food and Drug Administration (FDA) for the treatment of COVID-19 on December 22, 2021. These are peptidomimetic coronavirus main protease inhibitors. Nirmatrelvir is a proline derivative. The present patent describes similar proline- like compounds, their preparation, use, pharmaceutical composition, and treatment.

Automated summary

COVID-19 is treated with Paxlovid, a drug composed of Nirmatrelvir and Ritonavir, which obtained emergency use authorization from the FDA on December 22, 2021. These drugs are peptidomimetic inhibitors of the coronavirus main protease. The patent discusses similar proline-like compounds, their preparation, use, pharmaceutical composition, and treatment.